Jump to Main Contents
先端医療開発センター

Home > Yasuhito Uezono, MD, PhD

Yasuhito Uezono, MD, PhDYasuhito Uezono, MD, PhD

上園 保仁

As of 2017, the five-year survival rate for cancer patients has increased more than 60% due to the improvement of early-diagnosis techniques and state-of-the-art therapeutic technologies. However, the number of cancer survivors suffering the side effects of cancer chemotherapy has increased as well. In the Division of Supportive Care Research, we continue to develop novel compounds for intolerable pain and nausea/vomiting that decrease the quality of life of cancer patients. By such translational research, I want to innovate successful treatments for cancer patients.

Official title

  • Chief, Division of Supportive Care Research, Exploratory Oncology Research and Clinical Trial Center
  • Chief, Division of Cancer Pathophysiology, Research Institute
  • Staff Scientist, Innovation Center for Supportive, Palliative and Psychosocial Care, Hospital
  • Staff Scientist, Division of Health Care Research, Center for Public Health Sciences
  • Visiting Professor, Research Institute for Science & Technology (Translational Research Center), Tokyo University of Science
  • Visiting Professor, Kyushu University of Health and Welfare

Area of research

  • Molecular neuropharmacology
  • Palliative care research

Keywords

  • Opioid analgesia
  • G protein-coupled receptors
  • Palliative and supportive care
  • Non-labeled, real-time receptor assay

Current main research theme

  • Translational research for the development of novel analgesics for intolerable oral mucositis
  • Development of lipid signaling-modified compounds for treating intolerable pain
  • Development of novel clinically-available opioids with fewer side effects
  • Innovation of compounds for improving symptoms of cancer cachexia - clinical use of ghrelin or des-acyl ghrelin based on their molecular mechanisms of action

Collaborative research themes

  • G protein-coupled receptor-mediated signaling assay
  • Development of compounds to treat intolerable pain
  • Molecular and cellular mechanisms of action of Japanese herbal kampo medicine
  • Development of compounds and methods for the improvement of symptoms of cancer cachexia

Email

yuezono●ncc.go.jp(● replaccce to @)

Brief History

  • 1985  University of Occupational and Environmental Health, M.D.
  • 1989  University of Occupational and Environmental Health, M.D., Ph. D.
  • 1991  Postdoctoral Fellow, Division of Biology, California Institute of Technology
  • 2004  Associate Professor, Department of Molecular and Cellular Biology, Nagasaki University Graduate School of Biomedical Sciences
  • 2009  Chief, Division of Cancer Pathophysiology, National Cancer Center Research Institute
  • 2015  Chief, Division of Supportive Care Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center
  • 2015   Staff Scientist, Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital
  • 2015   Staff Scientist, Division of Health Care Research, Center for Public Health Sciences, National Cancer Center

Major affiliated societies

  • The Japanese Pharmacological Society(Executive board member、編集委員会委員、企画教育委員会委員)
  • Japan Society of Neurovegetative Research(Councilor)
  • The Japanese Society of Neuropsychopharmacology(Councilor)
  • Japanese Cancer Association
  • Japanese Society for Palliative Medicine
  • Japanese Society for Pharmaceutical Palliative Care and Sciences
  • The Japanese Society of Clinical Pharmacology and Therapeutics
  • Japanese Association of Supportive Care in Cancer

Major Publications

  1. Uezono Y, Miyano K, Sudo Y, Suzuki M, Shiraishi S, Terawaki K. A review of traditional Japanese medicines and their potential mechanism of action. Curr Pharm Des, 18:4839-4853, 2012. [PubMed]
  2. Miyano K, Sudo Y, Yokoyama A, Hisaoka-Nakashima K, Morioka N, Takebayashi M, Nakata Y, Higami Y, Uezono Y. History of the G protein-coupled receptor (GPCR) assays from traditional to a state-of-the-art biosensor assay. J Pharmacol Sci, 126:302-309, 2014. [PubMed]
  3. Fujitsuka N, Asakawa A, Morinaga A, Amitani MS, Amitani H, Katsuura G, Sawada Y, Sudo Y, Uezono Y, Mochiki E, Sakata I, Sakai T, Hanazaki K, Yada T, Yakabi K, Sakuma E, Ueki T, Niijima A, Nakagawa K, Okubo N, Takeda H, Asaka M, Inui A. Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1. Mol Psychiatry, 21:1613-1623, 2016. [PubMed]
  4. Terawaki K, Kashiwase Y, Sawada Y, Hashimoto H, Yoshimura M, Ohbuchi K, Sudo Y, Suzuki M, Miyano K, Shiraishi S, Higami Y, Yanagihara K, Hattori T, Kase Y, Ueta Y, Uezono Y. Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the kampo medicine rikkunshito on the model. PLoS One, 12:e0173113, 2017. [PubMed]
  5. Shindou H, Shiraishi S, Tokuoka SM, Takahashi Y, Harayama T, Abe T, Bando K, Miyano K, Kita Y, Uezono Y, Shimizu T. Relief from neuropathic pain by blocking of platelet-activating factor-pain loop. FASEB J, Epub ahead of print, 2017. [PubMed]